mouse anti-human braf v600e monoclonal antibody (clone ve1)  (Spring Bioscience)

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Lymphocyte biomarkers and distribution by BRAF mutation status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Mutagenesis

Journal: Annals of Surgical Oncology

Article Title: Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

doi: 10.1245/s10434-020-08713-1

Figure Lengend Snippet: Clinical response to DPCP correlated with OS by biomarker status

Article Snippet: For BRAF V600E IHC, Pleasanton, CA Spring Bioscience mouse anti-human BRAF V600E monoclonal antibody (Clone VE1) was used at a dilution of 1:200 run on a routine long program.

Techniques: Biomarker Discovery

Journal: Head and Neck Pathology

Article Title: Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis

doi: 10.1007/s12105-020-01166-8

Figure Lengend Snippet: Papillary thyroid carcinoma, classic type (a) showing diffuse cytoplasmic VE1 expression with moderate intensity (b); Papillary thyroid carcinoma, invasive follicular variant (c) showing negative VE1 immunostain (d). Evaluation of VE1 immunostain in papillary thyroid carcinoma at low power (e) may be deceptive. Higher power examination confirms diffuse but weak VE1 positivity (f) in a case with confirmed BRAF V600E mutation by next generation sequencing (unpublished data). These examples utilized prediluted Roche Ventana VE1 monoclonal antibody (Indianapolis, IN, USA) on the Leica Bond Refine System (Buffalo Grove, IL, USA) at 60 min incubation time

Article Snippet: The majority of the studies used the anti-human BRAF V600E (clone VE1) monoclonal antibody by Spring Bioscience (Spring Bioscience Pleasanton, CA, USA) [ 11 , 13 – 15 , 18 , 21 , 25 , 26 , 28 – 30 , 32 , 39 , 40 ] or Ventana medical systems (Ventana Medical Systems, Roche Diagnostics Indianapolis, IN, USA) [ 12 , 17 , 19 , 20 , 22 , 33 – 35 ].

Techniques: Expressing, Variant Assay, Mutagenesis, Next-Generation Sequencing, Incubation

Journal: Frontiers in Oncology

Article Title: BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas

doi: 10.3389/fonc.2018.00526

Figure Lengend Snippet: Clinical-pathological characteristics of patients and BRAF V600E immunostain intensity.

Article Snippet: As for immunohistochemistry, 3-micron paraffin embedded sections were dehydrated, pretreated with avidin block for 15' and biotin block for 15', then incubated with BSA for 30' and incubated with mouse anti-human BRAF V600E monoclonal antibody (clone VE1, Spring Bioscience) at room temperature for 60' (dilution 1:50, PT-link antigen retrival at high pH).

Techniques: Sequencing